Immunis, Inc.

06/23/2026

Hans S. Keirstead serves as Chairman of Immunis, a clinical-stage biotechnology company developing multi-active, stem cell-derived secretome therapies aimed at addressing age- and disease-related immune decline. The company’s lead investigational biologic, IMM01-STEM, is designed to harness beneficial stem cell factors to modulate multiple pathways involved in cell-to-cell communication, tissue development, and immune responses, to reduce susceptibility to disease.

A major milestone under Hans’ leadership came in January 2026, as Immunis released the first-ever Phase 2 data for a secretome-based biologic, demonstrating clinically meaningful weight loss with preserved muscle and improved gait speed in obese sarcopenic seniors.

Earlier in his career, Hans spent 15 years at the University of California, Irvine, where he served as a distinguished professor, mentored more than 100 students, published over 150 manuscripts, and helped establish and direct the $77 million Stem Cell Research Center. He holds a PhD in neuroscience from the University of British Columbia and completed postdoctoral studies at the University of Cambridge.

CONGRATULATIONS, DR. KEIRSTEAD!!!

06/22/2026

As Director of Medical Affairs at Immunis, Erin Curry oversees medical strategy and clinical research supporting regenerative therapy development for age-related disease. Erin is a board-certified Physician Assistant and applies a patient-centered approach across clinical planning and external medical engagement. Her work also reflects a focus on access for underserved populations.

Erin joined Immunis in its early days and has played a key role in shaping the company’s clinical priorities and culture. She is a core member of the team advancing IMM01-STEM, Immunis’ multi-active, cell-free biologic, supporting FDA-approved Phase 2 clinical trials across indications, including sarcopenia, osteoarthritis, and metabolic dysfunction. In 2025, she helped drive progress on Immunis’ placebo-controlled Phase 2 study in adults with sarcopenic obesity. This was an important milestone that expanded the IMM01-STEM pipeline and strengthened the company’s position in regenerative medicine.

Earlier in her clinical career, Erin worked in neurosurgery at Hoag Hospital and in neuro-oncology at St. Jude Medical Center, where she served as a sub-investigator on multiple clinical trials. Her global health work includes public health research in Kathmandu, Nepal, focused on zoonotic disease preparedness, along with ongoing volunteer service through disaster response and community health programs. Erin earned dual master’s degrees in physician assistant studies and public health from Touro University California.

CONGRATULATIONS, ERIN!!!!

06/22/2026

Immunis is tackling one of the most urgent challenges of aging: muscle loss that robs older adults of independence and quality of life.

In an interview with The Healthcare Technology Report, Chairman Dr. Hans Keirstead shares how Immunis is developing a novel, multi-factorial therapeutic approach aimed at preserving strength, function, and mobility in older adults.

If you’re interested in longevity, regenerative medicine, or the future of healthy aging, this is worth a watch.

https://youtu.be/rBi7z3C3fts?si=Cg147QVh95wLmRM0

Welcome to The Healthcare Technology Report, a leading information source on healthcare technology companies and solutions.In this episode, we speak with Han...

11/28/2025

According to Dr. Micah Drummond, “Muscle is one of the most influential factors in human healthspan.”

And we couldn't agree more!

Check out our conversation with Dr. Drummond on why muscle is important for healthy aging: https://immunisbiomedical.com/resources/muscle-and-healthspan/